Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome

Summary

To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in adult patients with AD.

Timeline

Start

2019-03-25

Primary completion

2019-12-28

Completion

2019-12-28

Drugs

Indications